Multicenter Registry of Common Femoral Artery Disease Treated With Endovascular Revascularization Using Interwoven
Kazunori Horie1, Mitsuyoshi Takahara2, Tatsuya Nakama3
1Department of Cardiovascular Medicine, Sendai Kousei Hospital, Sendai, Japan.
Summary
Endovascular therapy with interwoven nitinol stents (IWS) for common femoral artery (CFA) disease showed an 88.0% freedom from restenosis at 2 years. This EVT option is suitable for patients with comorbidities unsuitable for surgery.
Area of Science:
- Vascular Surgery
- Interventional Cardiology
- Biomaterials Engineering
Background:
- Surgical thromboendarterectomy is the standard for common femoral artery (CFA) disease.
- Endovascular therapy (EVT) is an alternative for patients with comorbidities.
- Interwoven nitinol stents (IWS) are designed to prevent stent fracture.
Purpose of the Study:
- To evaluate the feasibility and clinical outcomes of EVT using IWS for CFA lesions.
- To assess the 2-year restenosis rates after EVT with IWS in CFA disease.
Main Methods:
- Retrospective analysis of 177 patients with 199 CFA lesions treated with EVT using IWS (2019-2021).
- Primary endpoint: 2-year restenosis rate.
- Secondary endpoints: target-lesion revascularization, major amputation, and all-cause death rates.
Main Results:
- The 2-year freedom from restenosis was 88.0%.
- 2-year freedom rates were 92.9% for target-lesion revascularization, 99.0% for major amputation, and 75.2% for all-cause death.
- Factors associated with restenosis included smaller reference vessel diameter, EIA/SFA involvement, lower BMI, occluded DFAs, and CLTI.
Conclusions:
- EVT with IWS for CFA lesions demonstrates acceptable 2-year patency and may preserve CFA access.
- Factors like small RVD, EIA/SFA involvement, low BMI, occluded DFAs, and CLTI predict poorer outcomes.
- IWS implantation is a viable option for CFA lesions in patients unsuitable for surgical revascularization.
